{
  "abstract": "Older adults face a disproportionately high risk of severe influenza, yet the standard inactivated influenza vaccine (IIV) offers suboptimal protection in this population. This study evaluates the cost-effectiveness of replacing IIV with the recombinant influenza vaccine (RIV) for adults aged ≥50, ≥65, and ≥80 years in Hong Kong. We used a decision tree model to compare RIV with IIV for adults aged ≥50, ≥65, and ≥80 years in Hong Kong, from a societal perspective. Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were evaluated, and the impact of parameter uncertainty on the results was assessed via deterministic and probabilistic sensitivity analyses. We found that for adults ≥ 50 years, RIV increased total costs by USD 5.1 (HKD 39.8) per person and gained 0.00012 QALYs (ICER: USD 40,659 [HKD 317,140] per QALY) compared with IIV. Among adults ≥65 years, RIV cost USD 6.0 (HKD 46.8) more and gained 0.00021 QALYs (ICER: USD 29,077 [HKD 226,801] per QALY). For adults ≥80 years, RIV cost USD 3.2 (HKD 25.0) more and gained 0.00015 QALYs (ICER: USD 21,092 [HKD 164,518] per QALY). ICERs were less than willingness-to-pay thresholds of one to three times Hong Kong’s gross domestic product per capita. In conclusion, RIV is cost-effective compared with IIV for adults ≥50, ≥65, and ≥80 years in Hong Kong, with the lowest ICER observed in individuals ≥80 years.",
  "abstract_shown": true,
  "affiliations": [
    "World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, Pokfulam, China"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Shuyi Zhong"
    },
    {
      "affs": [
        0
      ],
      "name": "Irene O. L. Wong"
    },
    {
      "affs": [
        0
      ],
      "name": "Peng Wu"
    },
    {
      "affs": [
        0
      ],
      "name": "Benjamin J. Cowling"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/2yqkyhqfjkw42.bib",
  "cited_by": 0,
  "doi": "10.1080/21645515.2026.2757415",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13743053/",
  "id": "2yqkyhqfjkw42",
  "issns": [
    "2164-5515",
    "2164-554X"
  ],
  "landing_url": "https://doi.org/10.1080/21645515.2026.2757415",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Influenza"
    ],
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "2713|Influenza Virus Research Studies"
    ]
  ],
  "openalex": "W7134833479",
  "pdf_url": "https://www.tandfonline.com/doi/pdf/10.1080/21645515.2026.2757415?needAccess=true",
  "pmcid": "PMC13743053",
  "pmid": "42969388",
  "published": "2026-11-02",
  "publisher": "Taylor & Francis",
  "ris": "https://research.draconitic.com/paper/2yqkyhqfjkw42.ris",
  "sources": [
    {
      "first_seen": "2026-11-10T12:23:47Z",
      "native_id": "PMC13743053",
      "source": "pmc",
      "url": "https://doi.org/10.1080/21645515.2026.2757415"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2713|Influenza Virus Research Studies",
      "subfield": "epidemiology-public-health"
    }
  ],
  "title": "Cost-effectiveness of recombinant influenza vaccine compared with standard-dose influenza vaccine among adults 50 years of age and older in Hong Kong",
  "title_text": "Cost-effectiveness of recombinant influenza vaccine compared with standard-dose influenza vaccine among adults 50 years of age and older in Hong Kong",
  "type": "peer-reviewed",
  "updated_at": "2026-11-10T12:23:47Z",
  "url": "https://research.draconitic.com/paper/2yqkyhqfjkw42",
  "venue": "Human Vaccines & Immunotherapeutics",
  "versions": []
}